Cargando…
48-Month Clinical Outcomes and Prognostic Factors in an All-Comers Population with Acute Coronary Syndrome and Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention with a Sirolimus-Eluting Stent
We characterized the performance as well as safety of a second-generation thin-strut sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), deployed in the acute coronary syndrome (ACS) setting. We enrolled patients who were subjected to percutaneous coronary intervention...
Autores principales: | Tyczynski, Maciej, Kern, Adam, Buller, Patryk, Gil, Robert J., Bil, Jacek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672598/ https://www.ncbi.nlm.nih.gov/pubmed/38003888 http://dx.doi.org/10.3390/jpm13111573 |
Ejemplares similares
-
Clinical Outcomes and Prognostic Factors in Complex, High-Risk Indicated Procedure (CHIP) and High-Bleeding-Risk (HBR) Patients Undergoing Percutaneous Coronary Intervention with Sirolimus-Eluting Stent Implantation: 4-Year Results
por: Tyczyński, Maciej, et al.
Publicado: (2023) -
Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis
por: Bil, Jacek, et al.
Publicado: (2015) -
Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent
por: Gil, Robert J., et al.
Publicado: (2019) -
Sirolimus-eluting coronary stents: a review
por: Abizaid, Alexandre
Publicado: (2007) -
Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)